Wadden, PhD, from the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, and lead author of STEP 3, told Medscape Medical News in an email that "semaglutide 2.4 mg appears to be the breakthrough in weight management that healthcare providers and their patients with obesity have been waiting for." The mean 15% weight loss at 68 weeks is nearly twice what is seen with other FDA-approved anti-obesity medications, he noted, and moreover, 70% of patients taking semaglutide lost at least 10% of their initial weight, which is associated with clinically meaningful improvements in obesity-related type 2 diabetes, hypertension, obstructive sleep apnea, and impaired quality of life
Book a consult and well help you find the right path forward
Moreover, for those with dietary restrictions or absorption issues, regular B12 supplementation is crucial for long-term health
Given the high rates of obesity in this countrynot to mention the fact that 90 percent of all Wegovy sales are from the U.S.these figures are stark
BPC-157 + TB-500 5+5mg Pre-blended vial containing BPC-157 (Body Protection Compound, a 15 amino acid pentadecapeptide) and TB-500 (a synthetic fragment of thymosin beta-4)
The effects of improved glycemic control on complications in type 2 diabetes